Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Inhibition of phosphatidylinositol 3-kinase in lung myofibroblasts reduced symptoms of IPF in rodents and in vitro human samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Lung Extracellular Matrix and Fibroblast Function
White, E. S. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-240mg · Cited by 231
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224 · cited 1×
“Last, because many PI3Ki exhibit cross-inhibitory activity toward mammalian target of rapamycin (mTOR), we undertook to determine whether FAPL-PI3Ki1 might also suppress phosphorylation of an established substrate of mTOR, namely, 4E-BP1 (33).”
BackgroundExploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Acharya, P. S., Zukas, A., Chandan, V., Katzenstein, A.-L. A., & Puré, E. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.11.020 · Cited by 204
Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98
Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. A., Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0377-0 · Cited by 81
Cited by
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
“Progressive fibrosis leading to organ failure is considered the end-stage pathology of multiple diseases affecting the major organs, including but not limited to myocardial fibrosis [35], pulmonary fibrosis [36],”
BackgroundChivu-Economescu, M., Necula, L. G., Matei, L., Dragu, D., Bleotu, C., Sorop, A., Herlea, V., Dima, S., Popescu, I., & Diaconu, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063214 · Cited by 42
“The inhibitor effectively reduced collagen production, showing that collagen-producing cells could be an effective target in human lung fibrosis [70].”
BackgroundAn mTORC1‐Dependent Mouse Model for Cardiac Sarcoidosis
Bueno‐Beti, C., Lim, C. X., Protonotarios, A., Szabo, P. L., Westaby, J., Mazic, M., Sheppard, M. N., Behr, E., Hamza, O., Kiss, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030478 · Cited by 34
Metadata
- Authors
- Hettiarachchi, S. U., Li, Y.-H., Roy, J., Zhang, F., Puchulu-Campanella, E., Lindeman, S. D., Srinivasarao, M., Tsoyi, K., Liang, X., Ayaub, E. A., Nickerson-Nutter, C., Rosas, I. O., & Low, P. S.
- Venue
- Science Translational Medicine
- Published
- 2020-10-28
- Volume
- 12
- Issue
- 567
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3097119343
- Cited by
- 93
- References
- 7
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.